DCF Tool

UTHR

United Therapeutics Corp – Pharmaceutical Preparation Manufacturing
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
Analysis Results
Intrinsic Value $415.13
Latest Price $232.47
Relative Value 44% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Millions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 4.9%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 5.1%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 4.9%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 613 584
2024 644 583
2025 675 582
2026 708 581
2027 743 580
Terminal Value

Assuming the company was sold after the projection period at an exit multiple of 30, the terminal value of the company would be 22300 million. This corresponds to a present value of 16600 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 2910 million. Adding in the terminal value gives a total present value of 19500 million.

There are presently 46.9 million outstanding shares, so the intrinsic value per share is 415.13.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 3,380,300,000
Current Cash 2,838,700,000
Current Liabilities 343,200,000
Current Debt 0
Non-Cash Working Capital (NCWC) 198,400,000
Change in NCWC 110,900,000
EBIT 979,700,000
Tax Provision 223,300,000
Depreciation and Amortization 51,300,000
Capital Expenditure -138,800,000
Unlevered Free Cash Flow 772,964,285
Current Assets 2,323,600,000
Current Cash 1,930,700,000
Current Liabilities 305,400,000
Current Debt 0
Non-Cash Working Capital (NCWC) 87,500,000
Change in NCWC 78,600,000
EBIT 555,900,000
Tax Provision 118,100,000
Depreciation and Amortization 49,900,000
Capital Expenditure -120,800,000
Unlevered Free Cash Flow 453,056,490
Current Assets 2,167,200,000
Current Cash 1,835,000,000
Current Liabilities 323,300,000
Current Debt 0
Non-Cash Working Capital (NCWC) 8,900,000
Change in NCWC -156,700,000
EBIT 593,600,000
Tax Provision 124,100,000
Depreciation and Amortization 49,900,000
Capital Expenditure -59,300,000
Unlevered Free Cash Flow 312,199,076
Current Assets 1,864,500,000
Current Cash 1,485,900,000
Current Liabilities 463,000,000
Current Debt 250,000,000
Non-Cash Working Capital (NCWC) 165,600,000
Change in NCWC 90,100,000
EBIT -187,600,000
Tax Provision -60,500,000
Depreciation and Amortization 45,900,000
Capital Expenditure -83,700,000
Unlevered Free Cash Flow -135,300,000
Current Assets 1,768,000,000
Current Cash 1,415,900,000
Current Liabilities 276,600,000
Current Debt 0
Non-Cash Working Capital (NCWC) 75,500,000
Change in NCWC -300,000
EBIT 805,400,000
Tax Provision 169,700,000
Depreciation and Amortization 35,900,000
Capital Expenditure -184,400,000
Unlevered Free Cash Flow 476,501,989
Current Assets 1,447,900,000
Current Cash 927,400,000
Current Liabilities 444,700,000
Current Debt 0
Non-Cash Working Capital (NCWC) 75,800,000
Change in NCWC 34,300,000
EBIT 1,024,900,000
Tax Provision 351,600,000
Depreciation and Amortization 31,000,000
Capital Expenditure -86,300,000
Unlevered Free Cash Flow 535,602,612
Current Assets 1,424,800,000
Current Cash 1,050,800,000
Current Liabilities 332,500,000
Current Debt 0
Non-Cash Working Capital (NCWC) 41,500,000
Change in NCWC 155,374,000
EBIT 1,061,700,000
Tax Provision 346,500,000
Depreciation and Amortization 31,600,000
Capital Expenditure -43,200,000
Unlevered Free Cash Flow 858,483,762
Current Assets 1,275,335,000
Current Cash 953,772,000
Current Liabilities 440,824,000
Current Debt 5,387,000
Non-Cash Working Capital (NCWC) -113,874,000
Change in NCWC -14,703,000
EBIT 699,015,000
Tax Provision 392,798,000
Depreciation and Amortization 32,921,000
Capital Expenditure -49,792,000
Unlevered Free Cash Flow 404,551,334
Current Assets 974,197,000
Current Cash 695,539,000
Current Liabilities 504,310,000
Current Debt 126,481,000
Non-Cash Working Capital (NCWC) -99,171,000
Change in NCWC 85,566,000
EBIT 538,800,000
Tax Provision 185,106,000
Depreciation and Amortization 32,245,000
Capital Expenditure -47,439,000
Unlevered Free Cash Flow 419,265,467
Current Assets 909,013,000
Current Cash 688,534,000
Current Liabilities 687,674,000
Current Debt 282,458,000
Non-Cash Working Capital (NCWC) -184,737,000
Change in NCWC -197,247,000
EBIT 292,499,000
Tax Provision 104,343,000
Depreciation and Amortization 31,259,000
Capital Expenditure -31,910,000
Unlevered Free Cash Flow -14,828,526
Current Assets 668,470,000
Current Cash 479,205,000
Current Liabilities 176,755,000
Current Debt 0
Non-Cash Working Capital (NCWC) 12,510,000
Change in NCWC 66,111,000
EBIT 421,503,000
Tax Provision 136,229,000
Depreciation and Amortization 27,145,000
Capital Expenditure -111,905,000
Unlevered Free Cash Flow 272,550,594

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.